低分子肝素钙治疗急性脑梗死临床研究

目的:观察低分子肝素钙治疗急性脑梗死的疗效及对凝血功能的影响。方法:将120例急性脑梗死患者随机分为治疗组和对照组,对照组在常规治疗基础上加用复方丹参液,治疗组在常规治疗基础上加用低分子肝素钙。两组于治疗前及治疗后第10天分别作凝血功能检测;于治疗前和治疗后第21d对患者进行神经功能缺损评分。结果:治疗组总有效率与对照组相比有显著差异(P<0.01);两组用药前后血小板计数、血浆凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)及纤维蛋白原(FIB)无显著差异(P>0.05)。结论:低分子肝素治疗急性脑梗死安全、有效,且能改善21d时的神经功能和预后。

A clinical study of low-molecular-weight heparin calcium for acute carebral infarction

Objective: To investigate the efficacy of low-molecular-weight heparin calcium in treating patients with acute cerebral infarction and its impact on blood coagulation function. Methods: A total of 120 patients with acute cerebral infarction were randomly divided into 2 groups: the treatment group and the control group . Patients in control group were treated with routine method in conjunction with the Compound danshen injection. Those in treatment group were treated with the routine method plus low-molecular-weight heparin calcium injection. Function of blood coagulation was examined before initiation of therapy and 10 days after in both groups of patients. Neural function was evaluated by a neural function score system before and 21 days after treatment. Results: The accumulative efficacy for patients in the treatment group was significantly higher than that in control group (P<0.01). The quantity of blood platelet , plasma prothromin time (PT), activated thromboplastin time (APTT),and fibrinogen (FIB) in both groups demonstrated no significant difference before and after treatment (P>0.05). Conclusions: Treating patients with acute cerebral infarction by low-molecular-weight heparin calcium is both safe and effective. It can improve neural function and prognosis at 21 days.